Evaluation of Auranofin Loading within Ferritin Nanocages

Int J Mol Sci. 2022 Nov 16;23(22):14162. doi: 10.3390/ijms232214162.

Abstract

Auranofin (AF), a gold(I) compound that is currently used for the treatment of rheumatoid arthritis and is in clinical trials for its promising anticancer activity, was encapsulated within the human H-chain and the horse spleen ferritin nanocages using the alkaline disassembly/reassembly protocol. The aim of the work was to highlight possible differences in their drug loading capacity and efficacy. The drug-loaded ferritins were characterized via UV-vis absorption spectroscopy and inductively coupled plasma-atomic emission spectroscopy to assess AF encapsulation and to define the exact amount of gold atoms trapped in the Ft cavity. The crystal structures allowed us to define the nature of AF interaction with both ferritins and to identify the gold binding sites. Moreover, the biological characterization let us to obtain preliminary information on the cytotoxic effect of AF when bound to the human H-chain.

Keywords: anticancer activity; ferritin encapsulation; gold compounds; metal complex; metallodrugs; protein metalation.

MeSH terms

  • Animals
  • Antineoplastic Agents / chemistry
  • Auranofin* / chemistry
  • Auranofin* / pharmacology
  • Binding Sites
  • Ferritins* / chemistry
  • Ferritins* / metabolism
  • Gold / chemistry
  • Horses
  • Humans
  • Nanoparticle Drug Delivery System* / chemistry
  • Nanoparticle Drug Delivery System* / pharmacology

Substances

  • Antineoplastic Agents
  • Auranofin
  • Ferritins
  • Gold
  • Nanoparticle Drug Delivery System

Grants and funding

This research received no external funding.